The mission of the Pulmonary Fibrosis Foundation (PFF) is to serve as the trusted resource for the pulmonary fibrosis (PF) community by raising awareness, providing disease education, and funding research.
Health care professional resources available. Call or email the PFF Patient Communication Center.
Host an event, engage legislators, or distribute educational materials during Global PF Awareness Month.
Create an online tribute page to honor the memory of a loved one or show your support for a friend.
PFF Ambassador Diane Reichert and PFF Senior Medical Advisor for Patient Communications Dr. David J. Lederer participated in a nationwide radio media tour to inform the public about PF. Listen to selected clips from the tour.
The Pulmonary Fibrosis Foundation (PFF) is deeply saddened to learn of the passing of devoted pulmonary fibrosis (PF) advocate and board member emeritus, Daniel E. Beren.
Watch the WGN-TV Chicago story about the first two FDA approved drugs available in the US for people suffering with the fatal disease, pulmonary fibrosis. The report features Dr. Imre Noth, PFF Medical Advisory Board Member.
The Pulmonary Fibrosis Foundation (PFF) applauds the approval of Esbriet (pirfenidone) and OFEV (nintedanib) by the U.S. Food and Drug Administration (FDA) as the first disease-specific therapies for idiopathic pulmonary fibrosis (IPF) in the United States.
The Pulmonary Fibrosis Foundation has a four-star rating from Charity Navigator and is a Better Business Bureau accredited charity.